Secondary analysis of 2 RCTs (n=383) of treat-to-target allopurinol: serum urate <0.36 mmol/L at 12 months did not differ significantly between people with and without tophi (70.3% vs 73.6%; P=0.76), nor did absence of flares (71.4% vs 79.7%).
Secondary analysisn = 383
Stamp et al. Do People With Tophaceous Gout Require More Allopurinol for Good Clinical Outcomes? Analysis of 2 Randomized Controlled Trials of Allopurinol Dose Escalation